Beta-adrenergic receptor blockade attenuates the exercise-induced suppression of TNF-alpha in response to lipopolysaccharide in rats.
Stressful exercise has been found to reduce the proinflammatory cytokine response to lipopolysaccharide (LPS). In this study, we aimed to determine whether receptor antagonists for corticosterone or catecholamines would increase the LPS-induced tumor necrosis factor-alpha (TNF-alpha) response after exhaustive exercise. Female F344 rats were randomly assigned to one of five groups: control (vehicle), RU-486 (glucocorticoid receptor antagonist, 30 mg/kg)-, propranolol [nonselective beta-adrenergic receptor (AR) blockade, 30 mg/kg]-, atenolol (beta(1)-AR blockade, 30 mg/kg)-, or ICI 118551 (beta(2)-AR blockade, 30 mg/kg)-treated groups. Each antagonist was given intraperitoneally 30 min prior to exercise or control period. Exercised rats ran until exhaustion on a treadmill at gradually increasing speeds, from 10 to 36 m/min at 15% grade. Immediately postexercise or control period all rats were injected with LPS (1 mg/kg, i.v.). Plasma TNF-alpha was reduced by prior exercise to approximately 10% of that of sedentary controls (p < 0.01). Plasma TNF-alpha concentration in exercised RU-486-treated rats was significantly different than that of nonexercised rats (19.2%, p < 0.01) and not different from exercised rats. However, pretreatment of rats with the nonselective beta-AR blocker propranolol almost completely reversed the exercise-induced suppression of plasma TNF-alpha in response to LPS. beta(1)-AR pretreatment almost completely attenuated the exercise-induced suppression of LPS-induced plasma TNF-alpha while beta(2)-antagonism had a partial effect. These results indicate that exercise-induced catecholamines, acting through beta-ARs (especially the beta(1)-AR), are responsible for the exercise-induced suppression of plasma TNF-alpha after LPS administration.
Kitamura
Hiromi
H
Department of Health and Nutrition, Wayo Women's University, Chiba, Japan.
Shiva
Daisuke
D
Woods
Jeffrey A
JA
Yano
Hiromi
H
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000818:Animals; D002395:Catecholamines / Q000097:blood; D003345:Corticosterone / Q000097:blood; D005260:Female; D008070:Lipopolysaccharides / Q000009:adverse effects*; D010805:Physical Conditioning, Animal / Q000502:physiology*; D051381:Rats; D011916:Rats, Inbred F344; D014409:Tumor Necrosis Factor-alpha / Q000097:blood* / Q000187:drug effects*
D000319:Adrenergic beta-Antagonists; D002395:Catecholamines; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha; D003345:Corticosterone